BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1286@pharmaconomics
DTSTAMP:20260707T041346Z
DTSTART;VALUE=DATE:20260323
DTEND;VALUE=DATE:20260324
SUMMARY:VALN Phase 3 — PF-07307405 (LB6V)
DESCRIPTION:Phase 3 trial results for PF-07307405 (LB6V) in Lyme disease are due Mar 23\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1836564/000162828026020495/lymephase3readoutpressrele.htm\n\nTrack it: https://pharmaconomics.com/e/1286
URL:https://pharmaconomics.com/e/1286
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VALN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR